Regulus Therapeutics Future Growth

Future criteria checks 0/6

Regulus Therapeutics is forecast to grow earnings and revenue by 22.6% and 76.1% per annum respectively while EPS is expected to grow by 9.6% per annum.

Key information

22.6%

Earnings growth rate

9.6%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	76.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	29 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:7RG0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-123	N/A	N/A	3
12/31/2025	N/A	-85	N/A	N/A	6
12/31/2024	N/A	-48	N/A	N/A	6
9/30/2024	N/A	-42	-36	-36	N/A
6/30/2024	N/A	-35	-34	-33	N/A
3/31/2024	N/A	-31	-28	-27	N/A
12/31/2023	N/A	-30	-27	-27	N/A
9/30/2023	N/A	-29	-28	-27	N/A
6/30/2023	N/A	-28	-27	-27	N/A
3/31/2023	N/A	-29	-28	-27	N/A
12/31/2022	N/A	-28	-26	-26	N/A
9/30/2022	N/A	-29	-27	-27	N/A
6/30/2022	N/A	-30	-26	-26	N/A
3/31/2022	N/A	-29	-25	-25	N/A
12/31/2021	N/A	-28	-24	-24	N/A
9/30/2021	5	-22	-13	-13	N/A
6/30/2021	10	-15	-12	-12	N/A
3/31/2021	10	-16	-12	-12	N/A
12/31/2020	10	-16	-13	-13	N/A
9/30/2020	5	-19	-21	-21	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	0	-21	-22	-21	N/A
12/31/2019	7	-19	-20	-20	N/A
9/30/2019	7	-22	-19	-19	N/A
6/30/2019	7	-27	-26	-26	N/A
3/31/2019	7	-36	-32	-32	N/A
12/31/2018	0	-49	-43	-43	N/A
9/30/2018	0	-55	-50	-50	N/A
6/30/2018	0	-60	N/A	-51	N/A
3/31/2018	0	-68	N/A	-56	N/A
12/31/2017	0	-72	N/A	-59	N/A
9/30/2017	0	-77	N/A	-63	N/A
6/30/2017	0	-81	N/A	-67	N/A
3/31/2017	1	-81	N/A	-67	N/A
12/31/2016	1	-82	N/A	-57	N/A
9/30/2016	12	-69	N/A	-59	N/A
6/30/2016	14	-63	N/A	-55	N/A
3/31/2016	17	-62	N/A	-48	N/A
12/31/2015	21	-56	N/A	-50	N/A
9/30/2015	14	-71	N/A	-44	N/A
6/30/2015	13	-67	N/A	-41	N/A
3/31/2015	10	-58	N/A	-42	N/A
12/31/2014	8	-57	N/A	-40	N/A
9/30/2014	9	-36	N/A	-37	N/A
6/30/2014	14	-29	N/A	-33	N/A
3/31/2014	18	-24	N/A	-30	N/A
12/31/2013	20	-19	N/A	-28	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7RG0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 7RG0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 7RG0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 7RG0 is forecast to have no revenue next year.

High Growth Revenue: 7RG0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 7RG0's Return on Equity is forecast to be high in 3 years time

Regulus Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

New minor risk - Profitability

New major risk - Revenue and earnings growth

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations

New 90-day high: €1.58

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: €1.32

New 90-day high: €0.84

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding

New 90-day high: €0.52

Revenue beats expectations

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

New 90-day low - €0.38

New 90-day low - €0.53

First half earnings released

New 90-day high - €0.84

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies